1: In 2025, look out for a new section in @JHepatology: "Breakthroughs Beyond the Journal". Editorial-style analyses of pivotal liver research
2: My comment on work from @Cell_Metabolism showing that MI drives #MASH. The interaction between these two diseases works BOTH ways 👇
What’s the best way to implement the 2-step clinical care pathway for evaluating MASLD? Is it as effective as VCTE for all patients? Check out this paper in J Hep: https://t.co/kE14CUXC1A. Congrats to @TerryYip12 and the VCTE-Prognosis Study Team! 🎉 #MASLD#ClinicalResearch
A new blood-based biomarker for #MASH has been confirmed in diverse US and Chinese populations. Amazing collaboration among @CUHKMedicine, @UCSDHealth, and Wenzhou Medical University! Read more in Cell Metabolism: https://t.co/lQFPeMM1D6
Great new #GUTVideo by Su et al on
"Lactococcus lactis HkyuLL 10 suppresses colorectal tumourigenesis and restores gut microbiota through its generated alpha-mannosidase" via
https://t.co/423AIf0W4B
Paper via: https://t.co/Wrpq3uZ3ZN
@CUHKofficial@CUHKMedicine #ColorectalCancer
👋#LiverTwitter
What is your diagnosis❓
41yo woman: dark urine, scleral icterus, fatigue, shortness of breath, RUQ pain
➡️AST 364U/L
➡️ALT 393U/L
➡️ALP 155U/L
➡️Bilirubin 9.2 mg/dl
➡️Progestin-only OCP 7wks prior
History of photosensitivity
Case🔗https://t.co/nI19FXdflw
Achieving SVR doesn’t mean you’re free from liver cancer. The new AI-Safe-C score can identify patients at residual cancer risk. Stay informed! Congratulations, Huapeng! #Hepatology#LiverCancer#AI
https://t.co/vXm1nHQ7vY
🆕Article in press❕
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome
Read it here👉https://t.co/HiIlndIDee
#LiverTwitter
Excited to share our new review: "Food inequity and insecurity and MASLD: burden, challenges, and interventions"
https://t.co/WjKjcuzpuD, led by @SagiZelber, with @pericas_jm and more! @NatRevGastroHep#LiverTwitter
REVIEW
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Qi et al.
#LiverX@DrLoomba
https://t.co/YUWzpLHsxC
Possibly the most satisfying achievement for physician-scientists: When your proposal stands the test of time & defines clinical practice.
👉 @BavenoCoop for cACLD after HCV-cure ➡️ @EASLnews Position Paper 🔗 https://t.co/X1oy3dCewp @JHepatology
🫶 @GeorgSemmler@SaSi_Lens
"Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study" available open access at https://t.co/8GdUpnWYU5
#livertwitter
Published open access at https://t.co/AZgysVJeuC
"Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with IBD"
#GIwitter
Patients with covert HE has a higher probability of developing overt HE than patients with other causes of neurocognitive impairment (NI). Read the full paper by Sultanik et al 'open access' at https://t.co/8PmEL1yVT5
#GItwitter